SELLAS Life Sciences (SLS) Asset Writedowns and Impairment (2015 - 2017)
SELLAS Life Sciences' (SLS) quarterly Asset Writedowns and Impairment came in at -$3.6 million in Q4 2017, down 200.0% on a QoQ basis from $3.6 million in Q3 2017.
SELLAS Life Sciences (SLS) Asset Writedowns and Impairment (2015 - 2017) Analysis & Trends
SELLAS Life Sciences (SLS) has 2 years of Asset Writedowns and Impairment data on file, last reported at -$3.6 million in Q4 2017.
- On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to -$3.6 million in Q4 2017; TTM through Sep 2017 was $3.6 million, a 55.84% decrease from a year earlier, with the FY2021 full-year figure at $5.7 million, changed N/A from the prior year.
- Asset Writedowns and Impairment for Q4 2017 stood at -$3.6 million, down from $3.6 million in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for SLS reached as high as $8.1 million in Q3 2015 and fell as low as -$3.6 million in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | SELLAS Life Sciences | 3.23 Mn | 3.23 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | -3.56 Mn |
| Dec 31, 2017 | -3.56 Mn |
| Sep 30, 2017 | 3.56 Mn |
| Sep 30, 2017 | 3.56 Mn |
| Sep 30, 2015 | 8.07 Mn |
| Sep 30, 2015 | 8.07 Mn |